Effects of Xingnaojing on serum high-sensitivity C-reactive protein and neuron-specific enolase in patients with acute cerebral hemorrhage

A protocol of systematic review and meta-analysis

Zhe-ren Zhou, MMa, Yun-hua Zhao, MBb, Rong Sun, MBc, Yu-rong Zhang, MD, PhDd,∗

Abstract

Background: This study will systematically explore the effects of Xingnaojing (XNJ) on serum high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) in patients with acute cerebral hemorrhage (ACH).

Methods: We will comprehensively search the following electronic databases (MEDLINE, EMBASE, Cochrane Library, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure) from inception to the March 1, 2020. There are no limitations related to the language and publication status. Two authors will independently perform all citation identification, information extraction, and study quality. All potential conflicts will be solved through discussion with the help of a third author. RevMan 5.3 software will be used for data synthesis and statistical analysis.

Results: This study will summarize the present evidence to investigate the effects of XNJ on serum hs-CRP and NSE in patients with ACH.

Conclusion: This study may provide an impressive understanding of perspective from scientific basis for effects of XNJ on serum hs-CRP and NSE in patients with ACH.

Study registration: PROSPERO CRD42020171648.

Abbreviations: ACH = acute cerebral hemorrhage, hs-CRP = high-sensitivity C-reactive protein, NSE = neuron-specific enolase, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis, RCTs = randomized controlled trials, XNJ = Xingnaojing.

Keywords: acute cerebral hemorrhage, high-sensitivity C-reactive protein, neuron-specific enolase, xingnaojing

1. Introduction

Stroke occurs when the blood supply to the part of brain is interrupted or decreased. It is characterized by high incidence, disability, mortality, and recurrence rates. Among stroke conditions, acute cerebral hemorrhage (ACH) occurs as one of the highest incidence rates (varies from 50% to 80%) and disability rates (ranges from 50% to 70%). It accounts for 20% to 30% of all stroke disorders. Although a variety of treatments are available for ACH, they still suffer from satisfied results. Fortunately, traditional Chinese medicine has been utilized to treat stroke survivors effectively. Specifically, studies suggested that Xingnaojing (XNJ) has significant effects on serum high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) in patients with ACH. However, no systematic review has investigated the effects of XNJ on hs-CRP and NSE in patients with ACH. This systematic review aims to explore the effects of XNJ on hs-CRP and NSE in patients with ACH.

2. Methods and analysis

2.1. PROSPERO registration

This study protocol has been registered through PROSPERO (CRD42020171648). It is organized based on the Preferred
2.4.3. Types of participants. We will include all subjects who were diagnosed as ACH irrespective of religion, race, sex or place of birth.

2.4.4. Types of outcome measurements. The primary outcomes include serum hs-CRP and NSE in patients with ACH. The secondary outcomes are limb function (as measured by Fugl–Meyer Assessment scale, or related scales), muscle strength (as identified by the motricity index or connected tools), quality of life (as checked by activities of daily living scale or relevant scores), and adverse events.

2.4. Data collection and analysis
2.4.1. Selection of studies. Two authors will independently check titles/abstracts of retrieved records and all unrelated studies will be removed. Full texts of potential studies will be identified in details and determined for eligibility. We will record all excluded studies with specific reasons. We will demonstrate process of study selection in a PRISMA diagram chart. Any different opinions between 2 authors will be resolved by a third author through discussion.

2.4.2. Data extraction and management. A data extraction sheet will be designed previously to collect all essential information. Any conflicts between 2 authors will be settled down by a third author through discussion. The extracted information comprises of study characteristics (e.g., title, first author, and publication time), patient characteristics (e.g., age, sex, diagnostic criteria, and eligibility criteria), study setting, study methods, details of treatment and controls, outcome indicators, results, findings, and adverse events.

2.4.3. Missing data dealing with. We will request any unclear or missing data from original authors by email if it occurs. If such data is not obtainable, we will analyze available data only using intention-to-treat analysis.

2.5. Study quality evaluation
Two authors will independently assess study quality using Cochrane risk of bias tool. This tool covers 7 domains and is further rated as low, unclear and high risk of bias for each item. Any disagreements will be solved by a third author through consultation.

2.6. Statistical analysis
RevMan 5.3 software will be utilized to analyze extracted data and to perform statistical analysis. We will estimate continuous data as weighted mean difference or standard mean difference and 95% confidence intervals (CIs), and will express dichotomous data as risk ratio and 95% CIs. We will use I² statistic to test potential heterogeneity among included RCTs. I² ≤ 50% means homogeneity, and we will use a fixed-effects model, and will perform a meta-analysis if it is possible. I² > 50% suggests remarkable heterogeneity, and we will place a random-effects model, and will undertake a subgroup analysis to detect its possible sources. In addition, we will also conduct a narrative summary.

2.7. Additional analysis
2.7.1. Subgroup analysis. A subgroup analysis will be carried out to investigate the sources of considerable heterogeneity based on the variations in study characteristics, study quality, interventions and controls, and outcomes.
2.7.2. Sensitivity analysis. A sensitivity analysis will be explored to test the robustness of study findings by removing low quality study.

2.7.3. Reporting bias. A reporting bias will be checked by funnel plot and Eggers regression test if we will include more than 10 eligible studies.134-35

2.8. Ethics and dissemination

This study will not need ethical document, since it will not obtain individual subject data. This study is expected to be published at a peer-reviewed journal.

3. Discussion

Previous studies have hypothesized that XNJ plays a key role in treating ACH. It has effects on hs-CRP and NSE in patients with ACH.18-23 However, all conclusions are drawn based on the individual study, and all evidence is still at the conceptual level. In addition, no systematic review specifically has addressed this issue. Therefore, this is the first study to systematically investigate the effects on hs-CRP and NSE in patients with ACH. The results of this study will provide beneficial evidence for both clinical practice and future studies.

Author contributions

Conceptualization: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun, Yu-rong Zhang.

Data curation: Zhe-ren Zhou, Rong Sun, Yu-rong Zhang.

Formal analysis: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun.

Funding acquisition: Yu-rong Zhang.

Investigation: Yu-rong Zhang.

Methodology: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun.

Project administration: Yu-rong Zhang.

Resources: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun.

Software: Zhe-ren Zhou, Yun-hua Zhao.

Supervision: Yu-rong Zhang.

Validation: Zhe-ren Zhou, Yun-hua Zhao, Yu-rong Zhang.

Visualization: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun, Yu-rong Zhang.

Writing – original draft: Zhe-ren Zhou, Rong Sun, Yu-rong Zhang.

Writing – review & editing: Zhe-ren Zhou, Yun-hua Zhao, Rong Sun, Yu-rong Zhang.

References

[1] Liu Z, Zhou LJ, Sun Y, et al. Sufficient collateral blood supply from accessory middle cerebral artery in a patient with acute ischemic stroke. Intern Neurol J 2015;12:215-7.

[2] Nowinski WL, Qian G, Kargavil Nagaraja BP, et al. Analysis of ischemic stroke MR images by means of brain atlas of anatomy and blood supply territories. Acad Radiol 2006;13:1023–34.

[3] Cabrал NL, Nagel V, Conforto AL, et al. High five-year mortality rates of ischemic stroke subtypes: A prospective cohort study in Brazil. Int J Stroke 2019;14:491–9.

[4] Chin YY, Sakinah H, Arayti A, et al. Prevalence, risk factors and secondary prevention of stroke recurrence in eight countries from south, east and Southeast Asia: a scoping review. Med J Malaysia 2018;73:90–9.

[5] Díaz Guzmán J. Cardioembolic stroke: epidemiology. Neurologia 2012;27(Suppl 1):4–9.

[6] Ono H, Nishijima Y, Ohita S, et al. Hydrogen gas inhalation treatment in acute cerebral infarction: a randomized controlled study on safety and neuroprotection. J Stroke Cerebrovasc Dis 2017;26:2587–94.

[7] Wang S, Ma T, Wang L, et al. Effect of acupuncture on cerebrovascular reserve in patients with acute cerebral infarction: protocol for a randomized controlled pilot study. Trials 2017;18:292.

[8] Feigin VL, Lawes CM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43–53.

[9] Chan E, Anderson CS, Wang X, et al. Significance of intraventricular hemorrhage in acute intracerebral hemorrhage: intensive blood pressure reduction in acute cerebral hemorrhage trial results. Stroke 2015;46:653–8.

[10] Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cerebral hemorrhage. Curr Care Med 2010;38:637–48.

[11] Liao H, Xu J, Lin ZZ, et al. Effect of Tianhuang Granule on intracranial pressure and serum matrix metalloproteinase-9 in patients with acute cerebral hemorrhage. Chin J Integr Med 2010;16:304–8.

[12] Qureshi AI, Palech YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neuroradiol 2011;15:559–76.

[13] Xia ZY, Wang J, Guo JW, et al. Effect of Chinese drugs for breaking blood expelling stasis on acute cerebral hemorrhage: a prospective randomized double-blind controlled study. Zhongguo Zhong Xi Yi Jie He Za Zhi 2016;36:821–6.

[14] Fouda YA, Newsome AS, Spellicy S, et al. Minoicynode in acute cerebral hemorrhage: an early phase randomized trial. Stroke 2017;48:2885–7.

[15] Gao Z, Gao ZD, Wei YQ, et al. An investigation of the effect of Xingnaojing injection combined with edaravone in the treatment of acute cerebral hemorrhage and its effect on serum hs-CRP and NSE. Chin Tradit Med 2019;44:55–64.

[16] Huang J, Lin Z, Wang Q, et al. The effect of a therapeutic regimen of traditional Chinese medicine rehabilitation for post-stroke cognitive impairment: study protocol for a randomized controlled trial. Trials 2015;16:272.

[17] Zhao H, Yang D, Shi M, et al. Clinical efficacy and safety of traditional Chinese medicine combined with Western Medicine in patients with diabetic acute ischemic stroke. J Tradit Chin Med 2014;34:145–9.

[18] Zhang Y, Jin H, Ma D, et al. Efficacy of integrated rehabilitation techniques of traditional Chinese medicine for ischemic stroke: a randomized controlled trial. Am J Chin Med 2013;41:971–81.

[19] Gao Y, Zhong H, Ma B, et al. Randomized, double-blind, parallel-controlled clinical trial on correspondence of prescriptions and traditional Chinese medicine syndrome of ischemic stroke. J Tradit Chin Med 2012;32:335–42.

[20] Shi XL, Tang YY, Meng H. Xingnaojing injection combined with edaravone in the treatment of acute cerebral hemorrhage and its effect on serum hs-CRP and NSE. Chinese Fore Med Sci 2020;39:109–11.

[21] Luo L. The effect of Xingnaojing on acute cerebral hemorrhage and its effect on serum hs-CRP and NSE. Medical Inf 2019;32:149–51.

[22] Zhang ZY, Xiao Y, Wan LF. The effect of Xingnaojing injection on nerve function and C-reactive protein in patients with acute hypertensive cerebral hemorrhage. Hua Xia Med 2018;31:55–6.

[23] Cheng L. The effect of Xingnaojing on acute cerebral hemorrhage and the effects of serum hs-CRP and NSE. J Tradit Med 2018;32:101–2.

[24] Bao ZC, Zhang LY, Wu YP, et al. Efficacy of edaravone in the treatment of acute cerebral hemorrhage and its effect on serum hs-CRP, DD, NSE levels. Adv Mod Biomed 2017;17:118–21.

[25] Lu ZS, Zhang LC, Yang P, et al. Efficacy and safety of edaravone in the treatment of acute cerebral hemorrhage. Hua Xia Med 2018;31:55–6.

[26] Wang S, Ma T, Wang L, et al. Effect of acupuncture on cerebrovascular reserve in patients with acute cerebral infarction: protocol for a randomized controlled pilot study. Trials 2017;18:292.

[27] Wang RF, The effect of Xingnaojing injection combined with edaravone on hs-CRP and IL-6 in patients with acute cerebral hemorrhage. Asia Pacific Tradit Med 2017;13:132–3.

[28] Fang J. Clinical effect of Xingnaojing injection on acute cerebral hemorrhage and its effect on serum hs-CRP and NSE. Modern Diag Treat 2017;28:1997–9.
[29] Ma MH. The effect of Xingnaojing injection in the treatment of acute cerebral hemorrhage and its effect on serum high-sensitivity C-reactive protein. J Aeros Med 2016; 27:48–50.

[30] Fang AQ, Cui J. The effect of Xingnaojing injection on serum hs-CRP and IL-6 in patients with cerebral hemorrhage. China Higher Med Educ 2015;6:126–7.

[31] Gu HJ, Li G, Wan D. Clinical effect of Xingnaojing injection on acute cerebral hemorrhage and its effect on serum hs-CRP and NSE. Chinese J Exp Pharmacol 2014;20:178–82.

[32] Zhu CR, Xu CB. Effect of Xingnaojing injection on serum hs-CRP and IL-6 in patients with acute cerebral hemorrhage. J Nanjing Univ Tradit Chin Med 2013;29:280–2.

[33] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[34] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.

[35] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.